Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease
dc.contributor.author | McCarthy, Conor J. | en_US |
dc.contributor.author | Sheldon, Susan | en_US |
dc.contributor.author | Ross, Charles W. | en_US |
dc.contributor.author | McCune, William Joseph | en_US |
dc.date.accessioned | 2006-04-28T16:25:59Z | |
dc.date.available | 2006-04-28T16:25:59Z | |
dc.date.issued | 1998-08 | en_US |
dc.identifier.citation | McCarthy, Conor J.; Sheldon, Susan; Ross, Charles W.; McCune, W. Joseph (1998)."Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease." Arthritis & Rheumatism 41(8): 1493-1496. <http://hdl.handle.net/2027.42/37816> | en_US |
dc.identifier.issn | 0004-3591 | en_US |
dc.identifier.issn | 1529-0131 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/37816 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=9704650&dopt=citation | en_US |
dc.description.abstract | Objective To describe the myelodysplastic syndromes (MDS) and cytogenetic abnormalities that occur in patients who have been treated with alkylating drugs for their rheumatic disease. Methods Patients with rheumatic disease who developed MDS after current or previous treatment with alkylating drugs were selected for evaluation by chart review and cytogenetic studies. Results Eight patients with rheumatic disease (mean age 56.9 years) developed MDS over the study period. Seven had received oral cyclophosphamide and 1 chlorambucil as their main immunosuppressive drug. The mean total cumulative dose of cyclophosphamide or chlorambucil was 118 gm and 6.5 gm, respectively, over a period of 2-10 years. The cytogenetic abnormalities included adeletion of all or part of chromosome 7 in 5 patients, while 4 had a deletion of part of the long arm of chromosome 5. Six of the patients have since died. Conclusion Large cumulative doses of cyclophosphamide and chlorambucil were associated with the development of MDS, the occurrence of abnormalities of chromosome 5 and/or chromosome 7 deletions, and a poor prognosis. | en_US |
dc.format.extent | 452240 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | John Wiley & Sons, Inc. | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.title | Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Ann Arbor ; Department of Rheumatology, Mater Misericordiae Hospital, University College Dublin, Eccles Street, Dublin 7, Ireland. | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Ann Arbor | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Ann Arbor | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Ann Arbor | en_US |
dc.identifier.pmid | 9704650 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/37816/1/21_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/1529-0131(199808)41:8<1493::AID-ART21>3.0.CO;2-5 | en_US |
dc.identifier.source | Arthritis & Rheumatism | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.